Sold as Solosec. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Secnidazole (sold as Solosec), first approved Sep 15, 2017, with 3 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Solosec | Part D | $57K | +2% | 138 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and SecnidazoleTrichomonas Vaginitis, Bacterial Vaginitis · Tulane University | Phase 4 | Recruiting | Feb 15, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 15, 2017 | SolosecNDA 209363 · New molecular entity | Evofem Inc | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
